Physician profile
Sandra Doud
NPI 1316900756
$3,130.38
in general payments reported to CMS, 2019-2025
24 companies · $618 in 2025
The $618 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $433 · 2021: $146 · 2022: $847 · 2023: $348 · 2024: $352 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $485.17 | 2019-2023 | Acuvue |
| Alcon Vision LLC | $430.84 | 2019-2025 | Precision 1, Precision 7, Precision7 |
| Sun Pharmaceutical Industries INC. | $303.55 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $268.35 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sight Sciences, INC. | $235.25 | 2022-2025 | Omni Surgical System |
| Glaukos Corporation | $228.76 | 2022-2025 | Idosetr |
| Oyster Point Pharma, INC. | $215.50 | 2022-2025 | Tyrvaya, Ryzumvi |
| Optos, INC. | $127.77 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $121.85 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.65 | 2019-2021 | |
| Coopervision INC. | $93.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $93.43 | 2019-2023 | |
| Rxsight INC | $72.99 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Mallinckrodt Hospital Products INC. | $72.91 | 2020-2022 | |
| Abbvie INC. | $58.61 | 2022-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $43.67 | 2020-2022 | |
| Eyevance Pharmaceuticals LLC | $42.64 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $34.60 | 2021 | |
| Thea Pharma INC. | $21.90 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $21.06 | 2023 | Tecnis Iol, Healon Duet Pro |
| Dompe US, INC. | $16.53 | 2022 | |
| Ani Pharmaceuticals, INC. | $14.27 | 2022 | |
| Allergan, INC. | $13.88 | 2021 | |
| Biotissue Holdings INC. | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Doud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.